Literature DB >> 35115286

Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Study.

Nur Başak1, Berna Nilgün Özgürsoy Uran2, Elif Sarıtaş Yüksel3.   

Abstract

BACKGROUND: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics.
METHODS: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs. After creating a question pool with 40 items, the pilot study was applied with 70 patients. SPSS 25.0 and AMOS programs were used. Item-total correlation coefficients, Cronbach's alpha and test-retest analysis, missing data, extreme value, normality, 27% sub- upper item discrimination analysis, and exploratory and confirmatory factor analyses were used.
RESULTS: The factor structure of the scale was examined with exploratory and confirmatory factor analyses and the contribution of these components to the total variance was measured as 74.21%. The Anti-TNF Alpha Treatment Adherence Scale was found in relation to the scale structure consisting of 12 items and 4 sub-dimensions. According to the first level multifactorial analysis results, the goodness of fit identities of the scale were found at an acceptable level, with the following values: RMSEA 0.067; GFI 0.92; AGFI 0.87; CFI 0.95; andχ2 79.876 (P = .000).
CONCLUSION: It was determined that the Anti-TNF Alpha Treatment Adherence Scale represents the area to be measured, measures the researched structure, has a high internal consistency between items, is interrelated, and is consistent over time. As a result of all mea- surements, it was determined that it is a valid and reliable scale.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35115286      PMCID: PMC9153282          DOI: 10.5152/tjg.2022.211170

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  22 in total

1.  Exploratory factor analysis in behavior genetics research: factor recovery with small sample sizes.

Authors:  Kristopher J Preacher; Robert C MacCallum
Journal:  Behav Genet       Date:  2002-03       Impact factor: 2.805

Review 2.  Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.

Authors:  Karen van Hoeve; Ilse Hoffman; Severine Vermeire
Journal:  Expert Opin Drug Saf       Date:  2017-12-10       Impact factor: 4.250

3.  A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

Authors:  W Miehsler; G Novacek; H Wenzl; H Vogelsang; P Knoflach; A Kaser; C Dejaco; W Petritsch; M Kapitan; H Maier; W Graninger; H Tilg; W Reinisch
Journal:  J Crohns Colitis       Date:  2010-03-17       Impact factor: 9.071

4.  Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.

Authors:  Brian J Wentworth; Ross C D Buerlein; Anne G Tuskey; M Ashley Overby; Mark E Smolkin; Brian W Behm
Journal:  Inflamm Bowel Dis       Date:  2018-08-16       Impact factor: 5.325

Review 5.  Anti-TNF Therapy.

Authors:  Irina Udalova; Claudia Monaco; Jagdeep Nanchahal; Marc Feldmann
Journal:  Microbiol Spectr       Date:  2016-08

Review 6.  Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.

Authors:  Hiroki Mitoma; Takahiko Horiuchi; Hiroshi Tsukamoto; Naoyasu Ueda
Journal:  Cytokine       Date:  2016-08-24       Impact factor: 3.861

7.  Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.

Authors:  Laura Martelli; Anthony Lopez; Sophie Strobel; Silvio Danese; Xavier Roblin; Cédric Baumann; Laurent Peyrin-Biroulet
Journal:  J Dig Dis       Date:  2017-10       Impact factor: 2.325

8.  Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions.

Authors:  Maureen M Kelly; Barbara S Turner; Michael D Kappelman; Eun Jeong Lee; Ajay S Gulati
Journal:  Pediatr Qual Saf       Date:  2019-02-12

9.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28

Review 10.  Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review.

Authors:  Fanny Depont; Francis Berenbaum; Jérome Filippi; Michel Le Maitre; Henri Nataf; Carle Paul; Laurent Peyrin-Biroulet; Emmanuel Thibout
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.